PFIZER INC (PFE) Stock Price, Forecast & Analysis
NYSE:PFE • US7170811035
PFE Key Statistics, Chart & Performance
The current stock price of PFE is 27.755 USD. In the past month the price increased by 7.39%. In the past year, price increased by 7.6%.
PFE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PFE. When comparing the yearly performance of all stocks, PFE turns out to be only a medium performer in the overall market: it outperformed 64.53% of all stocks.
PFE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PFE. While PFE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
PFE Financial Highlights
Over the last trailing twelve months PFE reported a non-GAAP Earnings per Share(EPS) of 3.23. The EPS increased by 3.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.65% | ||
| ROA | 4.71% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.62 |
PFE Forecast & Estimates
33 analysts have analysed PFE and the average price target is 29.54 USD. This implies a price increase of 6.41% is expected in the next year compared to the current price of 27.755.
For the next year, analysts expect an EPS growth of -7.02% and a revenue growth -1.57% for PFE
PFE Ownership
PFE Latest News, Press Relases and Analysis
PFE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.1 | 981.56B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 589.194B | ||
| MRK | MERCK & CO. INC. | 22.44 | 295.956B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 121.86B | ||
| ZTS | ZOETIS INC | 18.54 | 55.368B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.69 | 25.86B | ||
| VTRS | VIATRIS INC | 6.25 | 18.186B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.2 | 12.317B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.49 | 9.222B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PFE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK 10017 US
CEO: Albert Bourla
Employees: 81000
Phone: 13026587581
PFIZER INC / PFE FAQ
What does PFIZER INC do?
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Can you provide the latest stock price for PFIZER INC?
The current stock price of PFE is 27.755 USD. The price increased by 1.04% in the last trading session.
Does PFE stock pay dividends?
PFIZER INC (PFE) has a dividend yield of 6.23%. The yearly dividend amount is currently 1.68.
What is the ChartMill technical and fundamental rating of PFE stock?
PFE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of PFE stock?
PFIZER INC (PFE) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for PFE stock?
The PE ratio for PFIZER INC (PFE) is 8.59. This is based on the reported non-GAAP earnings per share of 3.23 and the current share price of 27.755 USD.
Can you provide the upcoming earnings date for PFIZER INC?
PFIZER INC (PFE) will report earnings on 2026-04-27.